Risk Assessment (RA) is the key element of the Quality by Design (QbD) approach recommended by the pharmaceutical regulatory bodies. This research paper aimed to implement the regulatory requirements, the QbD thinking and the RA from the first steps of the oral peptide formulation development. The authors intended to give a general recommendation about the application possibilities of this methodology, to demonstrate the risk factors and the required decision points. Later, this paper presents a concrete development in practice. This case study shows the QbD and RA based early phase development of the GLP 1 analog, Liraglutide, an antidiabetic peptide drug mainly used in the treatment of type 2 Diabetes Mellitus. The objective here was to design Liraglutide encapsulated polymeric nanoparticles for oral delivery and the progress of their RA based development is presented. In this case, the particle size, the encapsulation efficiency, and the drug loading were found as the most critical quality attributes, the polymer concentration, the drug concentration, the w2/o ratio, the stabilizer concentration and polymer type were identified by the criticality rating as having the greatest impact on the product quality among the critical material attributes, finally the sonication time and sonication power were selected as the most critical elements of the production process. The results showed the importance of the risk factor-focused development in the oral peptide pharmaceutical formulations, and underlined the importance of the profound planning phase even in such cases. The formulation of an oral peptide delivery system is associated with several risks, but their priority ranking helps to focus on the resources (human, financial, time) related to the final product quality aimed at.
1. Background
Risk Assessment and the Quality by Design
The QbD approach is a holistic, systematic, knowledge and risk based methodology of pharmaceutical development approach, which is proactive and focuses on profound preliminary design (Yu et al., 2014; Yu, 2008) . It represents the main stream of the pharmaceutical technological formulation development nowadays (Pallagi et al., 2015; Bhise et al., 2017; Pallagi et al., 2016; Lee et al., 2017; Kovács et al., 2017) . QbD has several steps, which are described in the relevant guidelines of the International Council of Harmonisation (ICH), namely in the ICH Q8R2, Q9, Q10 papers (Pharmaceuticals International Conference on Harmonisation of Technical Requirements for Registration for Human Use, 2009; T. I. C. on Harmonisation, 2008; ICH Expert Working Group, 2005) . The implementation of QbD in the manufacturing of medicinal products is often called the "GMP of the 21st century"; regulatory authorities strongly force the pharmaceutical industry to apply this strategic planning approach (Lee et al., 2017; Kovács et al., 2017) . The adaptation and application of this methodology into the early research phases within the R&D activities holds many advantages, as mentioned in our previous papers. QbD based early development brings scientific results closer to the practical requirements and has a facilitating effect on industrial scale up and product transfer to the market. The main elements of QbD are: (1) the definition of the Quality Target Product Profile (QTPP), (2) the identification of the quality attributes and the selection of the Critical Quality Attributes (CQAs) related to the target product, (3) the prior selection of the production method and the identification of the Critical Process Parameters (CPPs), (4) performing of the initial Risk Assessment (RA). The results of RA will be the ordered CQAs and CPPs according to their calculated risk severity. The next step is the (5) setting up of the Design of Experiments (DoE) based on the highly risk related factors calculated previously in the RA step. This DoE is generally a factorial design and the aim is to determine the process and product Design Space (DS) (6), which means a multidimensional space and is determined by ranges of process elements and material attributes. Then it is needed to determine the Control Strategy (7), followed by the evaluation of the possibilities of Continuous Improvement (8). Risk Assessment is a key element in general, and it is especially advantageous in the case of complex drugs (e.g. peptides) and/or carrier systems of special risk (e.g. nano-delivery systems).
Peptide drug delivery and new formulation possibilities
The interest in the pharmaceutical technology utilizing therapeutic peptides in the treatment of a variety of diseases has dramatically increased over the past few years. However, these peptides suffer from several drawbacks, including metabolic liability, poor permeability across biological barriers, and fast hepatic clearance and subsequent inherent short half-lives, which all lead to the low bioavailability of such drugs. Hence, peptide administration is usually limited to parenteral routes such as subcutaneous, intravenous, and intramuscular administration, which are regarded as invasive routes associated with many downsides leading to insufficient patient adherence. Thus, a patient friendly non-invasive route of administration such as the oral route is desired in order to overcome the various drawbacks associated with the invasive delivery route. However, an orally administered peptide drug encounters numerous formidable obstacles, including chemical and enzymatic instability in addition to the limited ability to traverse biological barriers (Ahn et al., 2013) . Besides these barriers, the stability of the peptide drug during formulation and storage is a crucial aspect to be investigated when developing a peptide delivery system as peptides are sensitive drugs that can be damaged or become inactivate almost in every step of the production method (Patel et al., 2011) .
The selected drug for this case study is Liraglutide, a fatty acid modified glucagon like peptide-1 (GLP-1), which shares 97% amino acid sequence identity with human GLP-1, and is produced by recombinant technologies using yeast. This peptide drug was approved for the treatment of type 2 diabetes mellitus (Bode, 2012) , and Novo Nordisk has recently begun marketing it for the chronic weight management for obese or overweight adults who have associated comorbidities, such as hypertension, diabetes and dyslipidemia (Mehta et al., 2017) . Since Liraglutide is still delivered parenterally, the oral route should be aimed at, providing the patient friendly administration in addition to mimicking the physiological route of GLP-1 from intestine to circulation. Still, enhancing the oral bioavailability of Liraglutide presents an interesting challenge and the development of a novel oral Liraglutide delivery system is regarded as a high risk and high reward process.
Tremendous efforts have been devoted over the past decades to the oral administration of antidiabetic peptides. Based on our previous review and the evaluation of recently published papers in the field of antidiabetic peptide oral delivery (Ismail and Csóka, 2017; Ismail and Csoka, 2017a) , it can be concluded that among several techniques to improve antidiabetic peptide oral bioavailability, much of the success was recorded when using polymeric nanoparticles (NPs). And among the numerous polymers used to obtain polymeric NPs, poly lactic-coglycolic acid (PLGA) is the most widely used one, as it is a biodegradable and biocompatible synthetic polymer approved by the Food and Drug Administration (FDA, USA) (Malathi et al., 2015) . PLGA NPs were found to be successful in the protection of peptides from harsh environment in the gastrointestinal tract, thus enhancing stability, in addition to other merits of nanocarrier systems, which can all lead to improving the oral bioavailability of these drugs as in insulin, GLP-1 or its analogs (Ismail and Csoka, 2017a; Sharma et al., 2015; Araujo et al., 2016; Ismail and Csoka, 2017b) .
The aim of this study was to evaluate the role of RA in the case of the development of a Liraglutide drug delivery system for oral administration. Based on a careful collection, selection and evaluation of the relevant literature together with the previous developments of the research group in this field (Kovács et al., 2017; Karimi et al., 2016; Kovács et al., 2016) , we aimed to set up a strategic flow chart with proposed RA function and decision steps. The selected pilot study focused on novel Liraglutide loaded PLGA NPs prepared by means of the double emulsion solvent evaporation method and the application of the QbD concept in order to optimize the formulation by evaluating the effect of different formulation and process parameters on the quality of the aimed product.
Materials and methods

Materials
Liraglutide was purchased from Xi'an Health Biochem Technology Co., Ltd.
(China), Poly(lactide-co-glycolide) (PLGA 50:50, Mw = 30,000-60,000 Da), PVA (MOWIOL 4-88, MW = 27,000 Da), and D-(+)-Trehalose dihydrate (MW = 378.33 g/mol) were purchased from Sigma Aldrich (Germany). D-(-)-Mannit was purchased from Molar chemical KFT (Hungary). Sodium acetate anhydrous was purchased from Scharlam Chemie S.A. (Spain). Ethyl acetate which used for dissolving PLGA was from REANAL Labor (Hungary).
Methods
Knowledge space development
According to the QbD nomenclature, the collection and systematization of the relevant scientific literature and experience from the previous research is called "knowledge space development". The methodology was the analysis of the relevant scientific literature, structural development of data-collection. Modern quality management tools were used for visualization, such as preparation of Ishikawa diagrams (Ishikawa, 1976) and building up of flow charts for process description and systemic evaluation (Iso Iec, 1985) .
Definition of QTPP
The QTPP forms the basis of product development design. It should include patient-relevant product performance and characteristics related to the aimed therapeutic or clinical use. Considerations for QTPP selection are described in the ICH Q8R2 guideline, e.g. the route of administration, dosage form, delivery system, pharmacokinetic and other product quality criteria (e.g. sterility, stability and drug release), etc. The QTPP is always unique depending on the target.
Determination of the CQAs
Those factors which have critical influence on the QTPP linked with safety, quality or efficacy are CQAs. CQAs are generally associated with the drug substance, excipients, intermediates (in-process materials) and drug product. A CQA is a physical, chemical, biological, or microbiological property or characteristic of the output material (product) that should be within an appropriate limit, range, or distribution to ensure the desired product quality. CQAs are connected strictly to the product. The selection of CQAs needs carful design and a holistic view of the formulation development and is based on previous knowledge and experience.
Determination of the CMAs and CPPs
CMAs are critical material attributes, physical, chemical, biological, or microbiological properties or characteristics of an input material (Zhang and Mao, 2017) . CPPs are process parameters whose variability has a critical effect on the aimed product performance. CPPs and CMAs are linked to the selected production/formulation process. The selection of the CMA and CPP is based on prior knowledge, previous practical investigations and data from the relevant literature.
Initial Risk Assessment
Initial Risk Assessment aids in identifying which material attributes and process parameters potentially have an effect on product CQAs (ICH Q8R2). On the basis of prior knowledge and initial experimental data, RA tools can be used to identify and rank parameters (e.g. process, equipment and input materials) with the potential of impacting on final product quality. The initial RA was performed with Lean QbD Software (Lean QbD® Software, QbD Works LLC. USA, CA, Fremont) to evaluate the risks and get the Risk Priority Number (RPN) data. First, the interdependence rating was performed between CQAs and CMAs, CQAs and CPPs on a three-level scale and categorized as "high" (H), "medium," (M) or "low" (L). After the interdependence rating, an occurrence rating related to the selected CQAs, CMAs and CPPs was also made. The whole risk estimation resulted in calculated and ranked severity scores of CQAs, CMAs and CPPs, presented in Pareto charts generated by the software. The software also generates the relative occurrence-relative severity chart, depicting the critical factors in four different groups according to their estimated occurrence and severity (or the degree of their impact if they occur) estimated as the result of the RA. This affords a different presentation mode of the RA results. In this manner the upper right corner of the generated figure needs the highest attention as it represents those critical factors which have the highest risk of occurrence and have great impact on quality.
Generally, RA results show the factors with the highest impact on product quality, which are usually the key elements of the systemic designed experiments in practice.
Preparation of nanoparticles by double emulsion solvent evaporation technique
The process of the Liraglutide encapsulation by double emulsion solvent evaporation technique includes the following steps: first, formation of a primary w1/o emulsion, where the aqueous solution of the peptide drug is added to the polymeric organic solution upon sonication in ice bath. This was followed by the formation of a double emulsion (w1/o/w2) by dispersing the primary emulsion in an external aqueous phase containing poly vinyl alcohol PVA as a stabilizer, with the use of sonication in ice bath. Finally, organic solvent evaporation resulted in the formation of Liraglutide loaded nanoparticles.
Results
Theoretical evaluation of the Risk Assessment based oral peptide drug formulation development -General considerations
Oral peptide drug delivery has several challenges and many risks because peptide drugs are more complex and heterogeneous in nature than chemical drugs (Fosgerau and Hoffmann, 2015; Muheem et al., 2016; Lennernäs et al., 2014) . Every product is unique with several risks related (Bak et al., 2015) . Also, the European Medicine Agency (EMA) says that: "Biological products possess such a large number of quality attributes that it might not be possible to fully evaluate the impact on safety and efficacy of each one. Risk assessments can be performed to rank or prioritize quality attributes". So RA is a key element in the formulation of biological and even in the oral peptide delivery preparations. Fig. 1 presents the collected potential risk factors which should be taken into consideration when developing a new oral peptide dosage form (Fig. 1A) .
It is very important to note that besides the guidelines which describe the classical QbD (ICH Q82R, Q9 and Q10), an extension has to be made with the ICH Q11 guideline (European Medicines Agency, 2016) about the development and manufacturing of drug substances as shown in Fig. 1, part B ., since special attention needs to be paid when the active pharmaceutical ingredient is biological, like peptide.
In the next step of the knowledge space development phase of this study, the following Ishikawa diagram was set up as a result (Fig. 2.) . The Ishikawa diagram, as a quality management tool, can help to explore the cause and effect relationships. The diagram marks all the influencing factors related to peptide formulation for oral delivery in a detailed manner. These influencing factors can be the potential risks, namely CQAs, or CPPs depending on the aimed product. On the other hand, in the case of biologicals, the effect of the CQAs and CPPs on the QTPP are more difficult to understand, and the interactions are more complex with other risk aspects related to the safety, efficacy, immunogenicity, pharmacokinetics, bioactivity, etc. of the final drug product (Rathore, 2009 ). Rathore A. gives a thorough description of the relationships between the quality criteria of the biotechnology product and their safety and efficacy (Rathore and Winkle, 2009 ). On the other hand, the monoclonal antibody formulation study by Awotwe-Otoo et al. draws attention to the special elements of a biologic QTPP, such as elements regarding the reconstitution of previously lyophilized formula (e.g. reconstitution time, isotonicity, aggregation, etc.), which underlines the need for complex and careful thinking in this field (AwotweOtoo et al., 2012).
Besides the several different CQAs of a peptide formula, the formulation process development could have many additional problems, i.e. the technology transfer may be difficult due to the sensitive nature of the peptide drug as small changes in either the formulation composition or in the manufacturing steps can have great effect on the final quality (Winkle and Nasr, 2011; Jain, 2014) .
The flow chart, prepared by the authors illustrates the suggested decisions and their order when formulating a new dosage form containing a peptide drug substance (Fig. 3) .
The therapeutic target area ("unmet clinical need") should be defined first, which gives the main framework for the drug substance (active pharmaceutical ingredient, API) selection. The peptide type drug has to be characterized next, namely the physio-chemical properties, therapeutic activity profile, physical, chemical or structural stability, impurities, and the fact whether a surface modification is needed or not in order to fit the purpose. In connection with API profile building, it is required to define the desired therapeutic targeted place, either local or systemic. If the aimed effect is local, the drug size is not critical, immunogenicity is reduced, and there is no need for using permeability enhancers. If the new peptide formula is designed to have a systemic effect, the size is critical because of absorption, and the risk of immunogenicity is also increased. Immunogenicity is one of the most critical elements, so each aspect that has an influence or a potential influence on it needs special attention. Excipients could also be risk factors, as it is necessary to use permeability enhancers for better absorption, and enzyme inhibitors in order to protect the peptide from inactivation. This is also the point where the administration route of the planned new dosage form has to be decided. If the oral route is targeted, the following characteristics could be critical, for example: size, charge or electrostatic interactions, surface polarity, bioadhesive properties, lipophilicity, PEGylation, surface ligands. The dosage form selection is also part of the development design, and will be part of the QTPPs at the end as well. Depending on the targeted dosage form (e.g. conventional capsule, tablet like solid forms or emulsion, suspension, liquid formulas etc.), special considerations have to be made regarding excipients (permeation enhancers, protease inhibitors, enteric coating materials, artificial proteins, protective antibodies, etc.) and the proper production process has to be selected. Related to that phase of the design, the preliminary definition of other requirements is essential. These requirements include the dissolution profile, stability, impurities, permeability related characteristics, etc. The production process is also highly critical in the case of peptide formulation, due to their sensitivity. In this consideration, the selected manufacturing process has to be evaluated carefully from the risky aspects and the CPPs have to be selected. Other decisions should be made concerning regulatory and industrial expectations. From these aspects, costs planning can be a critical point of decision as there could be great differences in the marketing authorization costs between an originator and a biosimilar medicinal product.
The left part of Fig. 3 will generally give the basis of the QTPP definition, and the other sections of the chart could give the basis of the CQA and CPP selection for the different targeted peptide formulations. After the selection step the RA can be performed.
Practical implementation: Results of the Risk Assessment of a Liraglutide containing drug formulation development for oral deliveryPractical findings
The study presented below is intended to show how the previously introduced risk based theoretical model can be applied in the early phase of peptide drug containing formulation development. Based on reviewing the most relevant strategies (Ismail and Csóka, 2017) , Liraglutide loaded PLGA NPs are to be prepared by using the double Fig. 1 . Potential risks to be considered in the development of a new oral peptide containing drug (A) and steps of the extended QbD method (B). Fig. 2 . Ishikawa diagram for evaluating risks in general, related to the quality of an oral peptide drug development.
E. Pallagi et al. European Journal of Pharmaceutical Sciences 122 (2018) 160-169 emulsion solvent evaporation method, well-known (Sipos et al., 2005) as a suitable choice for encapsulating hydrophilic drugs, particularly protein and peptide drugs (Ramalho and Pereira, 2016; Iqbal et al., 2015) . According to the guideline, the initial step of this QbD based study aiming to design oral Liraglutide loaded PLGA NPs was to set up the QTPP as shown in Fig. 4 .
Then, the proposed CQAs that could critically affect the desired QTPP were identified. This was followed by selecting CMAs and CPPs that may have a significant effect on the CQAs of the lira-PLGA NPs, and the Ishikawa fish bone diagram (Wang et al., 2014) was constructed to illustrate these potential formulation and process variables likely to impact the quality of the lira-PLGA NPs (Fig. 5) .
The initial RA study was achieved by means of the "Lean QbD" software. Fig. 6 depicts the interdependence rating on the three-point scale between the selected CQAs and CMAs on the one hand, and CQAs and CPPs on the other hand.
The calculated and ranked severity scores for the CQAs, CMAs and CPPs are presented in Pareto charts generated by the Lean QbD Software as shown in Fig. 7 . E. Pallagi et al. European Journal of Pharmaceutical Sciences 122 (2018) 160-169 Besides, Fig. 8 presents the occurrence rating of the CMAs and CPPs, and here we selected the most potential factors with the highest occurrence and severity rate to be subjected to further investigation, applying a suitable design of experiment that enables the statistical optimization of the Liraglutide containing nanoparticles by defining the optimal value of each examined variable.
Discussion
The main steps and elements of oral peptide formulation development were evaluated as peptide type drug substance containing formulations can be handled as high risk dosage forms due to their complexity in both composition and preparation design. Initial Risk Assessment should be considered as a crucial part of the development process.
Classic drug development works with small, chemically manufactured active substance molecules. Biologic drugs, such as peptides, are biologically produced large molecules. Compared with conventional small drug formulation, peptide containing dosage form development has many challenges. For example, oral delivery systems for peptides need special considerations as the active agent has to be protected against digestion in the stomach and intestines, whereupon they become ineffective. The right technological formulation technique in addition to the proper selection of the excipients (permeation enhancers, protease inhibitors if needed, coating materials, etc.) could be the solutions to peptide stability and protection. The sensitivity of the biologicals should be the most focused area during their formulation development. In this regard, the main findings are the following: the prior ranking of the CQAs and CPPs which are mainly related to stability in the peptide formulation helps in more effective experimental design and the prioritization of the limited development sources. The identification of the relative risk levels at the beginning of product development has great advantages in such complex formulation.
The highly focused RA fields in peptide drug formulation are the following: (1) The drug substance, especially characteristics related to its stability and quality. (2) The manufacturing process, also related to the drug substance and product stability. Small changes in the production process could have a great effect on quality thus influencing the safety, efficacy and side effects related to the therapeutic application. These are strongly connected to the immunogenicity aspects (3).
Regarding the RA based study of Liraglutide encapsulated in PLGA NPs system prepared by double emulsion solvent evaporation technique for enhancing the oral bioavailability of this peptide drug, the QTPP was set up as presented in Fig. 6 based on prior knowledge regarding the peptide delivery, PLGA NPs formulation and methods of preparation, in addition to our initial experimental data. This was followed by the identification of CQAs, namely: particle size, zeta potential, polydispersity index (PDI), encapsulation efficiency (EE) and drug loading (DL). Then, initial RA was performed by identifying the CMAs and CPPs (regarding the double emulsion evaporation method) that may have a high risk of impacting the CQAs of the Liraglutide loaded PLGA nanoparticles (Yerlikaya et al., 2013) . Here, the Ishikawa fish bone diagram was constructed to configure the risk analysis process for defining the cause and effect relationship between the significant variables and the CQAs of the desired lira-PLGA NPs (Dhat et al., 2017) , and it can be seen from Fig. 7 that six main formulation (outer aqueous phase, inner aqueous phase, organic phase) and process (homogenization, centrifugation, freeze-drying) causes were identified. Further RA using E. Pallagi et al. European Journal of Pharmaceutical Sciences 122 (2018) [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] Lean QbD software showed that the most highly influential CPP (Figs. 6B, 7C, 8B) is sonication time, while the most highly influential CMAs (Figs. 6A, 7B, 8A) are polymer concentration, drug concentration, stabilizer concentration, cryoprotectant type, cryoprotectant concentration and external aqueous phase to organic phase ratio w2/o. To optimize process and formulation parameters, all these potential parameters will be subjected to further investigation with the use of a screening statistical design of experiment (Narayanan et al., 2014) in order to minimize their risk to a low level by controlling theses variables in a specific accepted range in order to obtain design space, thus assuring the desired CQAs values, to comply with the QTPP.
Conclusion
Several challenges and many risks are entailed in formulating dosage forms containing peptide drugs, which are more complex and heterogeneous in nature than chemical drugs. Thus, it is advisable to apply QbD based formulation development in order to save time and effort by directing the effort toward building the quality in each step of peptide delivery system development, which includes RA as an initial part of this QbD based process. This RA focused approach of the peptide pharmaceutical formulation development is essential as it results in ranked and prioritized risk factors, thereby leading to an effective formulation development. This study can help researchers to implement RA focused thinking and the QbD approach in their peptide formulation development if they follow the general steps of decisions presented Fig. 7 . Pareto charts A-Estimated severity scores of the proposed CQAs, B-Estimated severity rating of the proposed CMAs, C-Estimated severity rating of the proposed CPPs (PDI: polydispersity index, EE: encapsulation efficiency, DL: drug loading).
previously. In our pilot study, QbD oriented development was successfully implemented to gain understanding of critical parameters influencing the quality of the Liraglutide loaded PLGA NPs. Furthermore, the next step will be the application of a reliable and robust statistical DOE to investigate the effect of the most critical factors on CQAs with minimum number of runs, then determining the best optimum level of each variable which should be used to prepare an optimized formulation that assures the required CQAs. 
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